Literature DB >> 8981951

The molecular basis of partial penetrance of splicing mutations in cystic fibrosis.

N Rave-Harel1, E Kerem, M Nissim-Rafinia, I Madjar, R Goshen, A Augarten, A Rahat, A Hurwitz, A Darvasi, B Kerem.   

Abstract

The splicing variant, 5T allele, in intron 8 of the cystic fibrosis transmembrane conductance regulator (CFTR) gene was shown to be associated with partial penetrance of the clinical expression. This splicing variant leads to two possible transcripts: one normal and the other aberrantly spliced that lacks exon 9. The aim of this study was to analyze the molecular basis of the partial penetrance in individuals carrying the 5T allele. We analyzed the level of the correctly spliced RNA transcribed from the 5T allele in nasal and epididymal epithelium and correlated it with disease expression. Semiquantitative nondifferential reverse-transcriptase-PCR showed a considerable variability (6%-37%) in the total level of correctly spliced RNA transcribed from the 5T allele in nasal epithelium from 11 patients. A significant nonlinear correlation (r = .82, P = .002) between the level of the normal CFTR transcripts and the severity of lung disease was shown. No individuals with normal lung function and minimal or no lung disease (FEV1 >80% predicted) had <25% of normal transcripts, and individuals with <15% of normal transcripts did not have FEV1 >80%. The level of normal transcripts in epididymal epithelial cells from four infertile males with congenital bilateral absence of the vas deferens was low (6%-24%). In infertile males with normal lung function the level of correctly spliced transcripts in the nasal epithelium was higher than the level in the epididymal epithelium. These results indicate that there is variability in the efficiency of the splicing mechanism, among different individuals and between different organs of the same individual. This variability provides the molecular basis of the partial penetrance of cystic fibrosis disease in patients carrying the 5T allele.

Entities:  

Mesh:

Year:  1997        PMID: 8981951      PMCID: PMC1712544     

Source DB:  PubMed          Journal:  Am J Hum Genet        ISSN: 0002-9297            Impact factor:   11.025


  33 in total

1.  Leukocyte adhesion deficiency. Aberrant splicing of a conserved integrin sequence causes a moderate deficiency phenotype.

Authors:  T K Kishimoto; K O'Conner; T A Springer
Journal:  J Biol Chem       Date:  1989-02-25       Impact factor: 5.157

2.  DNA marker haplotype association with pancreatic sufficiency in cystic fibrosis.

Authors:  B S Kerem; J A Buchanan; P Durie; M L Corey; H Levison; J M Rommens; M Buchwald; L C Tsui
Journal:  Am J Hum Genet       Date:  1989-06       Impact factor: 11.025

3.  Correct splicing despite mutation of the invariant first nucleotide of a 5' splice site: a possible basis for disparate clinical phenotypes in siblings with adenosine deaminase deficiency.

Authors:  F X Arredondo-Vega; I Santisteban; S Kelly; C M Schlossman; D T Umetsu; M S Hershfield
Journal:  Am J Hum Genet       Date:  1994-05       Impact factor: 11.025

4.  Mutations in the cystic fibrosis gene in patients with congenital absence of the vas deferens.

Authors:  M Chillón; T Casals; B Mercier; L Bassas; W Lissens; S Silber; M C Romey; J Ruiz-Romero; C Verlingue; M Claustres
Journal:  N Engl J Med       Date:  1995-06-01       Impact factor: 91.245

5.  Differential cellular expression of cystic fibrosis transmembrane regulator in human reproductive tissues. Clues for the infertility in patients with cystic fibrosis.

Authors:  E F Tizzano; M M Silver; D Chitayat; J C Benichou; M Buchwald
Journal:  Am J Pathol       Date:  1994-05       Impact factor: 4.307

6.  Extensive analysis of 40 infertile patients with congenital absence of the vas deferens: in 50% of cases only one CFTR allele could be detected.

Authors:  T Casals; L Bassas; J Ruiz-Romero; M Chillón; J Giménez; M D Ramos; G Tapia; H Narváez; V Nunes; X Estivill
Journal:  Hum Genet       Date:  1995-02       Impact factor: 4.132

7.  A novel donor splice site in intron 11 of the CFTR gene, created by mutation 1811+1.6kbA-->G, produces a new exon: high frequency in Spanish cystic fibrosis chromosomes and association with severe phenotype.

Authors:  M Chillón; T Dörk; T Casals; J Giménez; N Fonknechten; K Will; D Ramos; V Nunes; X Estivill
Journal:  Am J Hum Genet       Date:  1995-03       Impact factor: 11.025

8.  Autosomal recessive hereditary congenital aplasia of the vasa deferentia in four siblings.

Authors:  T M Schellen; A van Straaten
Journal:  Fertil Steril       Date:  1980-10       Impact factor: 7.329

9.  Isolation of biologically active ribonucleic acid from sources enriched in ribonuclease.

Authors:  J M Chirgwin; A E Przybyla; R J MacDonald; W J Rutter
Journal:  Biochemistry       Date:  1979-11-27       Impact factor: 3.162

10.  Is congenital bilateral absence of vas deferens a primary form of cystic fibrosis? Analyses of the CFTR gene in 67 patients.

Authors:  B Mercier; C Verlingue; W Lissens; S J Silber; G Novelli; M Bonduelle; M P Audrézet; C Férec
Journal:  Am J Hum Genet       Date:  1995-01       Impact factor: 11.025

View more
  40 in total

Review 1.  The pathogenic consequences of a single mutated CFTR gene.

Authors:  U Griesenbach; D M Geddes; E W Alton
Journal:  Thorax       Date:  1999-08       Impact factor: 9.139

2.  A human model for multigenic inheritance: phenotypic expression in Hirschsprung disease requires both the RET gene and a new 9q31 locus.

Authors:  S Bolk; A Pelet; R M Hofstra; M Angrist; R Salomon; D Croaker; C H Buys; S Lyonnet; A Chakravarti
Journal:  Proc Natl Acad Sci U S A       Date:  2000-01-04       Impact factor: 11.205

3.  CFTR transcription defects in pancreatic sufficient cystic fibrosis patients with only one mutation in the coding region of CFTR.

Authors:  Molly B Sheridan; Timothy W Hefferon; Nulang Wang; Christian Merlo; Carlos Milla; Drucy Borowitz; Eric D Green; Peter J Mogayzel; Garry R Cutting
Journal:  J Med Genet       Date:  2010-11-20       Impact factor: 6.318

4.  Assessing the residual CFTR gene expression in human nasal epithelium cells bearing CFTR splicing mutations causing cystic fibrosis.

Authors:  Laia Masvidal; Susana Igreja; Maria D Ramos; Antoni Alvarez; Javier de Gracia; Anabela Ramalho; Margarida D Amaral; Sara Larriba; Teresa Casals
Journal:  Eur J Hum Genet       Date:  2013-10-16       Impact factor: 4.246

5.  A TOMM40 variable-length polymorphism predicts the age of late-onset Alzheimer's disease.

Authors:  A D Roses; M W Lutz; H Amrine-Madsen; A M Saunders; D G Crenshaw; S S Sundseth; M J Huentelman; K A Welsh-Bohmer; E M Reiman
Journal:  Pharmacogenomics J       Date:  2009-12-22       Impact factor: 3.550

6.  Correlating Cystic Fibrosis Transmembrane Conductance Regulator Function with Clinical Features to Inform Precision Treatment of Cystic Fibrosis.

Authors:  Allison F McCague; Karen S Raraigh; Matthew J Pellicore; Emily F Davis-Marcisak; Taylor A Evans; Sangwoo T Han; Zhongzhou Lu; Anya T Joynt; Neeraj Sharma; Carlo Castellani; Joseph M Collaco; Mary Corey; Michelle H Lewis; Chris M Penland; Johanna M Rommens; Anne L Stephenson; Patrick R Sosnay; Garry R Cutting
Journal:  Am J Respir Crit Care Med       Date:  2019-05-01       Impact factor: 21.405

7.  Whole-gene CFTR sequencing combined with digital RT-PCR improves genetic diagnosis of cystic fibrosis.

Authors:  Letizia Straniero; Giulia Soldà; Lucy Costantino; Manuela Seia; Paola Melotti; Carla Colombo; Rosanna Asselta; Stefano Duga
Journal:  J Hum Genet       Date:  2016-08-04       Impact factor: 3.172

Review 8.  Cystic fibrosis genetics: from molecular understanding to clinical application.

Authors:  Garry R Cutting
Journal:  Nat Rev Genet       Date:  2014-11-18       Impact factor: 53.242

Review 9.  Consensus on the use and interpretation of cystic fibrosis mutation analysis in clinical practice.

Authors:  C Castellani; H Cuppens; M Macek; J J Cassiman; E Kerem; P Durie; E Tullis; B M Assael; C Bombieri; A Brown; T Casals; M Claustres; G R Cutting; E Dequeker; J Dodge; I Doull; P Farrell; C Ferec; E Girodon; M Johannesson; B Kerem; M Knowles; A Munck; P F Pignatti; D Radojkovic; P Rizzotti; M Schwarz; M Stuhrmann; M Tzetis; J Zielenski; J S Elborn
Journal:  J Cyst Fibros       Date:  2008-05       Impact factor: 5.482

10.  Intragenic modifiers of hereditary spastic paraplegia due to spastin gene mutations.

Authors:  Ingrid K Svenson; Mark T Kloos; P Craig Gaskell; Martha A Nance; James Y Garbern; Shin-ichi Hisanaga; Margaret A Pericak-Vance; Allison E Ashley-Koch; Douglas A Marchuk
Journal:  Neurogenetics       Date:  2004-07-10       Impact factor: 2.660

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.